What is claimed is:

1. A compound of Formula (I):



(I)

wherein:

$R_3$ is a monocycle selected from the group consisting of $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

$R_4$ is a moiety selected from the group consisting of $C_2$-$C_{14}$ alkyl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein $R_4$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_5$ is a moiety selected from the group consisting of hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

$R_5$' and $R_5$" are independently selected from hydrogen, hydroxyl, halo, $C_{1-14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide, amino, acetamido and nitro;

$R_6$ is a group selected from the following formulae:



wherein:

$R_8$ is hydrogen, $C_1$-$C_3$ alkyl, $C_3$-$C_{10}$ cycloalkyl, or $C_1$-$C_{14}$ alkoxyl;

$R_{8'}$ is an $C_3$-$C_{14}$ alkyl, 2 to 9 membered heteroalkyl, acyl, $C_1$-$C_3$ alkyl-nitrile, $C_1$-$C_3$ alkyl-carboxamide, $C_1$-$C_4$ alkyl-heterocycloalkyl, $C_1$-$C_4$ alkyl-aryl, $C_1$-$C_4$ alkyl-heteroaryl, $C_3$-

$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with $R_8$ cyclizes to form an unsubstituted or substituted $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, or

, and

wherein $R_8$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_9$ is hydrogen, or a moiety selected from the group consisting of an $C_1$-$C_9$ alkyl, $C_2$-$C_9$ alkenyl, 2-9 membered heteroalkenyl, $C_1C_9$ alkylamide, $C_1$-$C_9$ alkyl-carboxamide, 2-9 membered heteroalkyl, $C_1$-$C_4$ alkyl-cycloalkyl, $C_1$-$C_4$ alkyl-heterocycloalkyl, $C_1$-$C_4$ alkyl-aryl, $C_1$-$C_4$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, and wherein $R_9$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_7$ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

wherein each $R_{10}$ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, $C_1$-$C_6$ alkoxyl, $C_1$-$C_{10}$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$-$C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10

membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_tO(CR_dR_e)_q$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein $R_a$ is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ $C_1$-$C_6$ alkyl, trifluoromethyl, $C_1$-$C_6$ alkoxyl, and trifluoromethoxy, $R_b$ and $R_c$ are independently selected from H, $C_1$-$C_6$ alkyl, $-(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$ (4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, $R_d$ and $R_e$ are independently H or $C_1$-$C_6$ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$, $-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and $-(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a $CH_3$ (methyl), $CH_2$ (methylene), or CH(methane) group which is not attached to a halogeno, SO or $SO_2$ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxyl and $-NR_dR_e$ wherein $R_d$ and $R_e$ are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

2. A compound of Formula (II):



**(II)**

wherein:

$R_4$ is a moiety selected from the group consisting of $C_2$-$C_{14}$ alkyl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, wherein $R_4$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_5$ is a moiety selected from the group consisting of hydroxyl, halo, $C_{1-14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

$R_5$' and $R_5$" are independently selected from hydrogen, hydroxyl, halo, $C_{1-14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide, amino, acetamido and nitro;

$R_6$ is a group selected from the following formulae:



wherein:

$R_8$ is hydrogen, $C_{1-3}$ alkyl, $C_3$-$C_{10}$ cycloalkyl, or $C_1$-$C_{14}$ alkoxyl;

$R_{8'}$ is an $C_3$-$C_{14}$ alkyl, 2-9 membered heteroalkyl, acyl, $C_1$-$C_3$ alkyl-nitrile, $C_1$-$C_3$ alkyl-carboxamide, $C_1$-$C_4$ alkyl-heterocycloalkyl, $C_1$-$C_4$ alkyl-aryl, $C_1$-$C_4$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with $R_8$ cyclizes to form a $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, or 
, and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_9$ is hydrogen, or a moiety selected from the group consisting of an $C_1$-$C_9$ alkyl, $C_2$-$C_9$ alkenyl, 2-9 membered heteroalkenyl, $C_1$-$C_9$ alkylamide, $C_1$-$C_9$ alkyl-carboxamide, 2-9 membered heteroalkyl, $C_1$-$C_4$ alkyl-cycloalkyl, $C_1$-$C_4$ alkyl-heterocycloalkyl, $C_1$-$C_4$ alkyl-aryl, $C_1$-$C_4$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, wherein $R_9$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_7$ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

wherein each $R_{10}$ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, $C_1$-$C_6$ alkoxyl, $C_1$-$C_{10}$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$-$C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl),

$-(CR_dR_e)_tO(CR_dR_e)_q(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10

membered heterocycloalkyl), -$(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein $R_a$ is selected from the group consisting of halo, hydroxyl, -$NR_dR_e$ $C_1$-$C_6$ alkyl, trifluoromethyl, $C_1$-$C_6$ alkoxyl, and trifluoromethoxy, $R_b$ and $R_c$ are independently selected from H, $C_1$-$C_6$ alkyl, -$(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), -$(CR_dR_e)_t$(aryl), -$(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and -$(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, $R_d$ and $R_e$ are independently H or C1-C6 alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -$OR_b$, -$C(O)R_b$, -$C(O)OR_b$, -$NR_bC(O)R_c$, -$C(O)NR_bR_c$, -$NR_bR_c$, -$NR_bOR_c$, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, -$(CR_dR_e)_t$($C_3$-$C_{10}$ cycloalkyl), -$(CR_dR_e)_t$(aryl), -$(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and –$(CR_dR_e)_t$(4-10 membered heteroaryl);

wherein any of the above-mentioned substituents comprising a $CH_3$ (methyl), $CH_2$ (methylene), or CH(methane) group which is not attached to a halogeno, SO or $SO_2$ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy and –$NR_dR_e$ wherein $R_d$ and $R_e$ are as defined above;

and wherein Ph means phenyl;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

3. A compound according to Claim 1 wherein $R_4$ is a phenyl;

$R_3$ is a monocycle selected from the group consisting of $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

$R_5$ is a moiety selected from the group consisting of hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

$R_5$' and $R_5$" are independently selected from hydrogen, hydroxyl, halo, $C_{1-14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide, amino, acetamido and nitro;

$R_6$ is a group selected from the following formulae:



wherein:

$R_8$ is hydrogen, $C_1$-$C_3$ alkyl, $C_3$-$C_{10}$ cycloalkyl, or $C_1$-$C_{14}$ alkoxyl;

$R_{8'}$ is an $C_{3-14}$ alkyl, 2-9 membered heteroalkyl, acyl, $C_{1-3}$ alkyl-nitrile, $C_{1-3}$ alkyl-carboxamide, $C_{1-4}$ alkyl-heterocycloalkyl, $C_{1-4}$ alkyl-aryl, $C_{1-4}$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with $R_8$ cyclizes to form a $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that $R_6$ is not



, and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_9$ is hydrogen, or a moiety selected from the group consisting of an $C_{1-9}$ alkyl, $C_{2-9}$ alkenyl, 2-9 membered heteroalkenyl, $C_{1-9}$ alkylamide, $C_{1-9}$ alkyl-carboxamide, 2-9 membered heteroalkyl, $C_{1-4}$ alkyl-cycloalkyl, $C_{1-4}$ alkyl-heterocycloalkyl, $C_{1-4}$ alkyl-aryl, $C_{1-4}$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that $R_6$ is not



, wherein $R_9$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_7$ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

wherein each $R_{10}$ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, $C_1$-$C_6$ alkoxyl, $C_1$-$C_{10}$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$-$C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl),

$-(CR_dR_e)_tO(CR_dR_e)_q(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein $R_a$ is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ $C_1$-$C_6$ alkyl, trifluoromethyl, $C_1$-$C_6$ alkoxyl, and trifluoromethoxy, $R_b$ and $R_c$ are independently selected from H, $C_1$-$C_6$ alkyl, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, $R_d$ and $R_e$ are independently H or $C_1$-$C_6$ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with 1 to 3 substituents

independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$, $-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a $CH_3$ (methyl), $CH_2$ (methylene), or CH(methane) group which is not attached to a halogeno, SO or $SO_2$ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy and $-NR_dR_e$ wherein $R_d$ and $R_e$ are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

4. A compound of Formula (IV):




wherein:

$R_3$ is a monocycle selected from the group consisting of $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

$R_4$ is a moiety selected from the group consisting of substituted or unsubstituted $C_2$-$C_{14}$ alkyl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl;

$R_5$ is a moiety selected from the group consisting of hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

$R_5$' and $R_5$" are independently selected from hydrogen, hydroxyl, halo, $C_{1-14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide, amino, acetamido and nitro;

$R_7$ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

$R_8$ is hydrogen, $C_1$-$C_3$ alkyl, $C_3$-$C_{10}$ cycloalkyl, or $C_1$-$C_{14}$ alkoxyl;

$R_{8'}$ is an $C_{3-14}$ alkyl, 2-9 membered heteroalkyl, acyl, $C_{1-3}$ alkyl-nitrile, $C_{1-3}$ alkyl-carboxamide, $C_{1-4}$ alkyl-heterocycloalkyl, $C_{1-4}$ alkyl-aryl, $C_{1-4}$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, or together with $R_8$ cyclizes to form a $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl or 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, or

, and wherein $R_{8'}$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_9$ is hydrogen, or a moiety selected from the group consisting of an $C_{1-9}$ alkyl, $C_{2-9}$ alkenyl, 2-9 membered heteroalkenyl, $C_{1-9}$ alkylamide, $C_{1-9}$ alkyl-carboxamide, 2-9 membered heteroalkyl, $C_{1-4}$ alkyl-cycloalkyl, $C_{1-4}$ alkyl-heterocycloalkyl, $C_{1-4}$ alkyl-aryl, $C_{1-4}$ alkyl-heteroaryl, $C_3$-$C_{10}$ cycloalkyl, 3-10 membered heterocycloalkyl, aryl and 3-10 membered heteroaryl, with the proviso that $R_6$ is not


, wherein $R_9$ is unsubstituted or substituted with 1 to 4 $R_{10}$ groups;

$R_7$ is a moiety selected from the group consisting of hydrogen, hydroxyl, halo, $C_1$-$C_{14}$ alkyl, $C_1$-$C_{14}$ alkoxyl, acyl, amide and nitro;

wherein each $R_{10}$ is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxyl, $C_1$-$C_6$ alkoxyl, $C_1$-$C_{10}$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-C(O)R_a$, $-C(O)OR_b$, $-OC(O)R_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $-S(O)_j(C_1$-$C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_t$(4-10 membered heteroaryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(aryl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qC(O)(CR_dR_e)_t$(4-10 membered heteroaryl),

$-(CR_dR_e)_tO(CR_dR_e)_q(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(aryl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_tO(CR_dR_e)_q$(4-10 membered heteroaryl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(aryl), and $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heterocycloalkyl), $-(CR_dR_e)_qSO_2(CR_dR_e)_t$(4-10 membered heteroaryl), wherein $R_a$ is selected from the group consisting of halo, hydroxyl, $-NR_dR_e$ $C_1$-$C_6$ alkyl, trifluoromethyl, $C_1$-$C_6$ alkoxyl, and trifluoromethoxy, $R_b$ and $R_c$ are independently selected from H, $C_1$-$C_6$ alkyl, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl), wherein q and t are each independently an integer from 0 to 5, $R_d$ and $R_e$ are independently H or $C_1$-$C_6$ alkyl, wherein 1 or 2 ring carbon atoms of the heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic and heteroaryl moieties of the foregoing $R_{10}$ groups are unsubstituted or substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR_b$, $-C(O)R_b$, $-C(O)OR_b$, $-NR_bC(O)R_c$, $-C(O)NR_bR_c$, $-NR_bR_c$, $-NR_bOR_c$, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $-(CR_dR_e)_t(C_3$-$C_{10}$ cycloalkyl), $-(CR_dR_e)_t$(aryl), $-(CR_dR_e)_t$(4-10 membered heterocycloalkyl), and

$-(CR_dR_e)_t$(4-10 membered heteroaryl);

and wherein any of the above-mentioned substituents comprising a $CH_3$ (methyl), $CH_2$ (methylene), or CH(methane) group which is not attached to a halogeno, SO or $SO_2$ group or to a N, O, or S is unsubstituted or substituted with a substituent from the group selected from hydroxyl, halo, $C_1$-$C_4$ alkyl, $C_1$-$C_4$ alkoxy and $-NR_dR_e$ wherein $R_d$ and $R_e$ are as defined above;

or a pharmaceutically acceptable salt of a compound of the Formula (I), or a multimer, prodrug or pharmaceutically active metabolite of a compound of the Formula (I) or pharmaceutically acceptable salt thereof.

5. A compound according to Claim 1 having the structure:









and multimers, pharmaceutically acceptable salts, prodrugs, and active metabolites thereof.

6. A pharmaceutical composition comprising an effective amount of an agent to inhibit cellular proliferation and a pharmaceutically acceptable carrier, said agent being selected from the group consisting of compounds, multimers, pharmaceutically acceptable salts, prodrugs, and active metabolites as defined in any of claims 1, 2, 3, and 4.

7. A method of inhibiting a CDK selected from CDK2, CDK4, CDK6 or CDK complex, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3, and 4.

8. A method of treating cellular proliferative diseases, comprising administering an effective amount of a compound, multimer, pharmaceutically acceptable salt, prodrug, or active metabolite as defined in any of claims 1, 2, 3 and 4.

9. A method according to claim 8, wherein the disease is cancer, autoimmune disease, viral disease, fungal disease, neurodegenerative disorder or cardiovascular disease.